medigraphic.com
ISSN 1560-4381 (Print)

2019, Number 4

<< Back Next >>

Correo Científico Médico 2019; 23 (4)

In vitro effectiveness of amikacin and fosfomicin in uropathogenic and multidrug resistant Escherichia coli strains

Cabrera RLE, Díaz RL, Miralles SAI, Ones RR, Torres HY, Pantaleón HM

Language: Spanish
References: 27
Page:
PDF size: 454.90 Kb.


ABSTRACT

Introduction: the urinary tract infections acquired in the community caused by multidrug resistant Escherichia coli strains, are a growing phenomenon in the world.
Objective: to determine the antimicrobial susceptibility, the resistance patterns and to find out the amikacin and fosfomycin sensitivity of the isolated multidrug resistant strains.
Methods: we developed a descriptive retrospective study in the period from June 1st , 2017 to December 31st , 2018. The universe we worked with was formed by 265 isolated Escherichia coli strains of ambulatory patients, with suspected urinary tract infections, who belonged to two health institutions: Aleida Fernandez Chardiet Hospital and the Municipal Hygiene, Epidemiology and Microbiology Center, in Güines Municipality, Mayabeque Province, Cuba.
Results: amikacin, fosfomicin and nitrofurantoin presented over 90 % of effectiveness. Antimicrobial resistance of isolated Escherichia coli was most common to ceftazidime (72%), followed by trimethoprim – sulfamethoxazole (61.5%), nalidixic acid (61.1%) and ciprofloxacin (52.8%). The strains showed a resistance pattern from three to nine antibiotics. Nalidixic acid and trimethoprim – sulfamethoxazole were found in most of the multiresistance patterns. Notice that in some profiles, ciprofloxacin has been also included. From the 265 isolated strains of Escherichia coli, 147 (55.4%) were multidrug resistant; and from those, 87% showed higher sensitivity to fosfomycin and amikacin.
Conclusions: trimethoprim - sulfamethoxazole and quinolones have a high resistance percentage.Fosfomycin and amikacin can be considered suitable therapeutic options for Escherichia coli multidrug resistant strains, based on the sensitivity studied.The results obtained from this study are a reason for epidemiological concern, and require a strict follow-up in the coming years.


REFERENCES

  1. Pigrau C. Infección del tracto urinario. Barcelona: Salvat; 2013.

  2. Ten Doesschate T, Van Mens SP, Van Nieuwkoop C, Geerlings SE, Hoepelman AIM, Bonten MJM. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).BMC Infect Dis. 2018[citado 5 ene 2019];18(1):626-631. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280543/

  3. Yábar MN, Curi Pesantes B, Torres CA, Calderón Anyosa R, Riveros M, Ochoa TJ. Multiresistance and factors associated with the presence of extended-spectrum beta-lactamases in Escherichia coli strains isolated from urine culture. Rev Peruana Med Exp Salud Pública. 2017[citado 5 ene 2019];34(4):660-665.Disponible en: https://europepmc.org/abstract/med/29364420

  4. Garza Montúfar ME, Treviño Valdez PD, De la Garza Salinas LH. Resistencia bacteriana y comorbilidades presentes en pacientes urológicos ambulatorios con urocultivos positivos. Rev Med Inst Mexicano Seguro Soc. 2018[citado 5 ene 2019;56(4):347-353.Disponible en: https://www.medigraphic.com/pdfs/imss/im-2018/im184f.pdf

  5. Ghazvini H, Taheri K, Edalati E, Sedighi M, Mirkalantari S. Virulence factors and antimicrobial resistance in uropathogenic Escherichia coli strains isolated from cystitis and pyelonephritis. Turk J Med Sci. 2019[citado 5 ene 2019]; 49(1):361-367. Disponible en: https://dergipark.org.tr/tr/download/article-file/735784

  6. Oliveira FA, Paludo KS, Arend LN, Farah SM, Pedrosa FO, Souza EM, et al. Virulence characteristics and antimicrobial susceptibility of uropathogenicEscherichia coli strains. Genet Mol Res. 2011[citado 5 ene 2019];10(4):4114-4125. Disponible en: https://www.geneticsmr.com/year2011/vol10-4/pdf/gmr1396.pdf

  7. Torres Fuentes G, Brito Herrera B, Barbier Rubiera A. Comportamiento de la infección urinaria y susceptibilidad antimicrobiana de la bacteria más frecuente. Rev Cubana Med Gen Integr. 2014[citado 5 ene 2019];30(4):416-425.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252014000400003

  8. Cabrera Rodríguez LE, Díaz Rigau L, Fernández Núñez T, Díaz Oliva S, Carrasco Miraya A, García Fumero Y, et al. Susceptibilidad antimicrobiana de aislados bacterianos en pacientes hospitalizados y comunitarios. Rev Cubana Med Trop. 2018[citado 5 ene 2019];70(2):1-10.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602018000200003

  9. Koneman E, Allen S, Janda W, Schreckenberger P, Washington W. Diagnóstico microbiológico. 5ta ed. Madrid: Panamericana; 1999.

  10. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 26th Ed. USA: Clinical Laboratory Standards Institute;2016[citado 15 may 2018].Disponible en: http://ljzx.cqrmhospital.com/upfiles/201601/20160112155335884.pdf

  11. Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012[citado 18 feb 2019]; 18(3): 268–281. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-0691.2011.03570.x

  12. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011[citado 18 feb 2019];52(5):103-120. Disponible en: https://academic.oup.com/cid/article/52/5/e103/388285

  13. Mama M, Manilal A, Gezmu T, Kidanewold A, Gosa F, Gebresilasie A. Prevalence and associated factors of urinary tract infections among diabetic patients in Arba Minch Hospital, Arba Minch province, South Ethiopia. Turk J Urol. 2018[citado 18 feb 2019];45(1):56-62. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342569/

  14. Zamudio Chávez O, Méndez Tovar S, Apodaca Tomas K, Cruz Hernández M. Estudio de sensibilidad de fosfomicina en enterobacterias y microorganismos multidrogorresistentes de muestras de pacientes del Hospital General «Dr. Gaudencio González Garza» del CMN La Raza. Rev Latinoam Patol Clin Med Lab .2017 [citado 10 mar 2019]; 64 (3): 114-119.Disponible en: https://www.medigraphic.com/pdfs/patol/pt-2017/pt173c.pdf

  15. Azargun R, Soroush Barhaghi MH, Samadi Kafil H, Ahangar Oskouee M, Sadeghi V, Memar MY, et al. Frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran. J Glob Antimicrob Resist. 2018[citado 18 feb 2019]; 17: 39-43. Disponible en: https://www.sciencedirect.com/science/article/pii/S2213716518302194

  16. Asafo Adjei K, Mensah JE, Labi AK, Dayie NTKD, Donkor ES. Urinary Tract Infections among Bladder Outlet Obstruction Patients in Accra, Ghana: Aetiology, Antibiotic Resistance, and Risk Factors. Diseases. 2018 [citado 18 feb 2019];6(3): 65-70.Disponible en: https://www.mdpi.com/2079-9721/6/3/65

  17. Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, et al. Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report. Open Access J Gerontol Geriatr Med. 2018[citado 18 feb 2019];4(3). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241532/

  18. Gutema T, Weldegebreal F, Marami D, Teklemariam Z. Prevalence, Antimicrobial Susceptibility Pattern, and Associated Factors of Urinary Tract Infections among Adult Diabetic Patients at Metu Karl Heinz Referral Hospital, Southwest Ethiopia. Int J Microbiol. 2018[citado 18 feb 2019];2018:7591259. Disponible en: https://www.hindawi.com/journals/ijmicro/2018/7591259/abs/

  19. Cantón R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, et al. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017). Rev Española Quimioter. 2019 [citado 18 feb 2019]; 32(2): 145-155. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441989/

  20. Demir T, Buyukguclu T. Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates. J Glob Antimicrob Resist. 2017 [citado 18 feb 2019];8: 164-168. Disponible en: https://www.sciencedirect.com/science/article/pii/S2213716517300127

  21. Cardone S, Petruzziello C, Migneco A, Fiori B, Spanu T, D'Inzeo T, et al. Age-related Trends in Adults with Urinary Tract Infections Presenting to the Emergency Department: A 5-Year Experience. Rev Recent Clin Trials. 2019 [citado 20 feb 2019];14(2):147-156. Disponible en: https://europepmc.org/abstract/med/30588887

  22. Lifonzo Mucha SJ, Tamariz Zamudio PE, Champi Merino RG. Sensibilidad a fosfomicina en Escherichia coli productoras de betalactamasas de espectro extendido. Rev Peruana Med Exp Salud Pública. 2018 [citado 20 feb 2019];35(1):68-71. Disponible en: http://www.scielo.org.pe/pdf/rins/v35n1/a11v35n1.pdf

  23. Gobernado M. Fosfomicina. Rev Española Quimioter. 2003[citado 20 feb 2019];16(1):15-40.Disponible en: https://seq.es/wp-content/uploads/2010/06/seq_0214-3429_16_1_15.pdf

  24. Strand L, Jenkins A, Henriksen IH, Allum AG, Grude N, Kristiansen BE. High levels of multiresistance in quinolone resistant urinary tract isolates of Escherichia coli from Norway; a non clonalphenomen? BMC Res Notes. 2014 [citado 20 feb 2019];7:376. Disponible en: https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-7-376

  25. Malekzadegan Y, Khashei R, Ebrahim Saraie H, Jahanabadi Z. Distribution of virulence genes and their association with antimicrobial resistance among uropathogenic Escherichia coli isolates from Iranian patients. BMC Infect Dis. 2018 [citado 20 feb 2019];18(1):572. Disponible en: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3467-0

  26. Suárez Trueba B, Milián Samper Y, Espinosa Rivera F, Hart Casares M, Llanes Rodríguez N, Martínez Batista ML. Susceptibilidad antimicrobiana y mecanismos de resistencia de Escherichia coli aisladas a partir de urocultivos en un hospital de tercer nivel. Rev Cubana Med. 2014 [citado 20 feb 2019];53(1): 3-13.Disponible en: http://scielo.sld.cu/pdf/med/v53n1/med02114.pdf

  27. González Mesa L, González Leyva MA, Zayas Tamayo AM, Curbelo Álvarez M, Garrido Nicot Y. Relación genética de aislados clínicos de Escherichia coli productores de Beta-Lactamasas de Espectro Extendido (BLEE) en un hospital de la Habana, Cuba. Rev CENIC Cienc Biológ. 2017 [citado 20 feb 2019];48(3):107-112. Disponible en: https://www.redalyc.org/pdf/1812/181253610005.pdf




2020     |     www.medigraphic.com